Если бронхит продолжается...

1. Заболеваемость населения России в 2007 г. Статистические материалы Минздравсоцразвития России 2008 г.
2. Irwin RS, Boulet L-P, Cloutier MM et al. Managing cough as a defense mechanism and as a symptom: a consensus panel report of the American College of Chest Physicians. Chest 1998; 114 (Suppl.): 133S–81S.
3. Terminology, definitions, and classification of chronic pulmonary emphysema and related conditions: Ciba Guest Symposium Report. Thorax 1959; 14: 286–99.
4. Mason RJ, Murray JF, Broaddus VC, Nadel JA. Textbook of Respiratory Medicine. Fourth Edition, Elsevier inc., USA 2005; 1: 872.
5. Wenzel RP, Fowler AA. Acute Bronchitis N Engl J Med 2006; 355 (20): 2125–30.
6. Braman SS. Postinfectious cough: ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (suppl.): 138S–46S.
7. Davis SF, Sutter RW, Strebel PM et al. Concurrent outbreaks of pertussis and Mycoplasma pneumoniae infection: clinical and epidemiological characteristics of illnesses manifested by cough. Clin Infect Dis 1995; 20: 621–8.
8. Wright SW, Edwards KM, Decker MD et al. Pertussis infection in adults with persistent cough. JAMA 1995; 13: 1044–6.
9. Palombini BC, Villanova CA, Araujo E et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest 1999; 116: 279–84.
10. Morice AH and committee members The diagnosis and management of chronic cough. Eur Respir J 2004; 24: 481–92.
11. Brightling CE, Ward R, Goh KL et al. Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med 1999; 160: 406–10.
12. Morice AH, Kastelik JA. Cough 1: Chronic cough in adults. Thorax 2003; 58: 901–7.
13. Lalloo UG, Barnes PJ, Chung KF. Pathophysiology and clinical presentations of cough. J Allergy Clin Immunol 1996; 98 (Suppl. 5): S91–6.
14. Irwin RS, Baumann MH, Bolser DC. Diagnosis and Management of Cough Executive Summary: ACCP Evidence-Based Clinical Practice Guidelines Chest. 2006; 129 (suppl.): 1S–23S.
15. Рациональная фармакотерапия заболеваний органов пищеварения. Под ред. В.Т.Ивашкина. М.: Литтерра, 2003.
16. Irwin RS, Zawacki JK, Curley FJ et al. Chronic cough as the sole presenting manifestation of gastroesophageal reflux. Am Rev Respir Dis 1989; 140: 1294–300.
17. Irwin RS, Zawacki JK. Accurately diagnosing and successfully treating chronic cough due to gastroesophageal reflux disease can be difficult. Am J Gastroenterol 1999; 94: 3095–8.
18. Webb WR. High-resolution computed tomography of obstructive lung disease. Radiol Clin North Am 1994; 32: 745–57.
19. Tan H, Buyukavci M, Arik A. Tourette's syndrome manifests as chronic persistent cough. Yonsei Med J 2004; 45: 145–9.
20. Jankovic J. Tourette's syndrome. N Engl J Med 2001; 345: 1184–92.
21. McGarvey LP, Warke TJ, McNiff C et al. Psychogenic cough in a schoolboy: evaluation using an ambulatory cough recorder. Pediatr Pulmonol 2003; 36: 73–5.
22. Mello C, Irwin RS, Curley FJ. The predictive values of the character, timing, and complications of chronic cough in diagnosing its cause. Arch Intern Med 1996; 156: 997–1003.
23. Irwin RS, Glomb WB, Chang AB. Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines. Chest 2006; 129 (suppl.): 174S–9S.
24. Shim CS, Williams MH Jr. Cough and wheezing from beclomethasone dipropionate aerosol are absent after triamcinolone acetonide. Ann Intern Med 1987; 106: 700–3.
25. Irwin RS, Zawacki JK, Wilson MM et al. Chronic cough due to gastroesophageal reflux disease: Falure to resolve despite total/near total elimination of oesophageal acid. Chest 2002; 121: 1132–40.
26. Birring SS, Brightling CE, Symon FA et al. Idiopathic chronic cough: association with organ specific autoimmune disease and bronchoalveolar lymphocytosis. Thorax 2003; 58: 1066–70.
27. Sekizava K, Jia YH, Ebihara T et al. Role of substance P in cough Pulm. Pharmacol 1996; 9: 323–8.
28. Dicpinigaitis PV, Rauf K. The influence of gender on cough reflex sensitivity. Chest 1998; 113 (5): 1319–21.
29. Irwin RS, Ownbey R, Cagle P. Interpreting the Histopathology of Chronic Cough. A Prospective, Controlled, Comparative Study Chest 2006; 130: 362–70.
30. Linder J, Sim I. Antibiotic treatment of acute bronchitis in smokers. J Gen Intern Med 2002; 17: 230–4.
31. Gonzales R, Brrtlett J, Besser R et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. Ann Intern Med 2001; 134: 521–9.
32. Snow V, Mottur-Pilson C, Gonzales R. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001; 134: 518–20.
33. Anthonisen N, Connett J, Kiley J et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of COPD. JAMA 1994; 272: 1497–505.
34. Smucny J, Flynn C, Becker L et al. Beta2-agonists for acute bronchitis. Cochrane Database Syst Rev (database online), 2004.
35. McCrory D, Brown C, Gelfand S et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190–209.
36. Schroeder K. Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults BMJ 2002; 324 (7333): 329.
37. Rubin BK, Ramirez O, Ohar JA. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis. Chest 1996; 109 (2): 348–52.
38. Kuhn JJ, Hendley JO, Adams KF et al. Antitussive effect of guaifenesin in young adults with natural colds. Chest 1982; 82: 713–8.
39. Elkins MR, Robinson M, Rose BR et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF)Study Group. A controlled trial of long-term inhaled hypertonicsaline in patients with cystic fibrosis. N Engl J Med 2006; 354 (3): 229–40.
40. Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirol 2005; 10 (1): 46–56.
41. King M, Brock G, Lundell C. Clearance of mucus by simulated cough. J Appl Physiol 1985; 58 (6): 1776–82.
42. Frohock JI, Wijkstrom-Frei C, Salathe M. Effects of albuterol en antiomers on ciliary beat frequency in ovine tracheal epithelial cells. J Appl Physiol 2002; 92 (6): 2396–402.
43. Daviskas E, Anderson SD, Eberl S et al. Effects of terbutaline in combination with mannitol on mucociliary clearance. Eur Respir J 2002; 20 (6): 1423–9.
44. Bernard D, Goepp JG, Duggan AK et al. Is oral albuterol effective for acute cough in non-asthmatic children? Acta Paediatr 1999; 88: 465–7.
45. Littenberg B, Wheeler M, Smith DS. A randomized controlled trial of oral albuterol in acute cough. J Fam Pract 1996; 42: 49–53.
46. Weich DJ, Viljoen H, Sweetlove MA et al. Investigation into the effect of Fenoterol onmucociliary clearance in patients with chronic bronchitis. Eur J Nucl Med 1988; 14 (11): 533–7.
47. Isawa T, Teshima T, Hirano T et al. Effect of oral salbutamol on mucociliary clearance mechanisms in the lungs. Tohoku J Exp Med 1986; 150 (1): 51–61.
48. Bennett WD Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002; 110 (6 Suppl.): S291–7.
49. Anzueto A, Jubran A, Ohar JA et al. Effects of aerosolized surfactant in patients with stable chronicbronchitis: a prospective randomized controlled trial. J Am MedAssoc 1997; 278 (17): 1426–31.
50. Bruce K. Rubin. Mucolytics, Expectorants, and Mucokinetic Medications Respir Care 2007; 52 (7): 859–65.
51. Olivieri D, Zavattini G, Tomasini G et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Respiration 1987; 51 (suppl. 1): 42–51.
52. Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis: clinical trial in 120 patients at two different doses. Respiration 1987; 51 (Suppl. 1): 37–41.
53. Valenti S, Marenco G. Italian multicenter study on the treatment of chronic obstructive lung disease with bromhexine. A double-blind placebo-controlled trial Respiration 1989; 56 (1–2): 11–5.
54. Guyatt GH, Townsend M, Kazim F, Newhouse MT. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92 (4): 618–20.
55. Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331 (10): 637–42.
56. Ramsey BW, Astley SJ, Aitken ML et al. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis 1993; 148 (1): 145–51.
57. Laube B, Auchi R, Shields D et al. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 1996; 153 (2): 752–60.
58. Puchelle E, Zahm JM, de Bentzmann S et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 1996; 9 (4): 765–9.
59. Gerrits CM, Herings RM, Leufkens HG, Lammers JW. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (5): 795–8.
60. Boman G, Backer U, Larsson S et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64 (6): 405–15.
61. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebocontrolled trial. Lancet 2005; 365 (9470): 1552–60.
62. Rogers DF. Mucoactive Agents for Airway Mucus Hypersecretory Diseases Respiratory Care 2007; 52 (9): 1176–97.
63. Dorow P, Weiss T, Felix R, Schmutzler H. Effect of a secretolytic and a combination of pinene, limonene and cineole on mucociliary clearance in patients with chronic obstructive pulmonary disease. Arzneimittelforschung 1987; 37 (12): 1378–81.
64. Behrbohm H, Kaschke O, Sydow K. The influence of a secretolytic drug on mucociliary clearance of the maxillary sinus. J Rhinol 1997; 4 (1): 29–33.
65. Roos U, Wulkow R, Wortha HP et al. Freie Radikale in Pathogenese und Therapie von entz?ndlichen Erkrankungen des Bronchialsystems, in: Meister R, Entz?ndliche Erkrankungen des Bronchialsystems, Springer Verlag, 1. Auflage 2000, Seiten 1–25.
66. Beuscher N, Kietzmann M, Bien E, Champeroux P. Interference of Myrtol standardised with inflammatory and allergic mediators. Arzneim-Forsch/Drug Res 1998; 48 (II), 985–989 et al. A randomised, multi-centered, placebo controlled phase III double blinded study with parallel group comparison to investigate the efficacy of Myrtol standardized capsules (4x300 mg oral daily) for patients with acute sinusitis. 92/334. Myrtol standardisiert Dokumentation 1994.
67. Hippeli S et al. Freie Radikale in Pathogenese und Therapie von entzndlichen Erkrankungen des Bronchialsystems, in: Meister R, Entzndliche Erkrankungen des Bronchialsystems, Springer Verlag, 1. Auflage 2000, Seiten 1–25.
68. Christoph F, Kaulfers P-M, Stahl-Biskup E. In vitro evaluation of the antibacterial activity of beta-triketones admixed to Melaleuca oils. Planta Med 2001; 67: 768–71.
69. Matthys H, de Mey C, Carls C et al Efficacy and Tolerability of Myrtol Standardized in Acute Bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs cefuroxime and ambroxol, Arzneim.-Forsch. Drug Res 2000; 50 (8): 700–11.
70. Wittig Th. GeloMyrtol® und GeloMyrtol® forte in Patients with Acute Sinobronchitis. A posteriori Analysis, August 2008. Study N° 94-0234 G.PohlBoskamp GmbH & Co. KG.
71. Meister R, Wittig Th, Beuscher N, de Mey C, Wirksamkeit und Vertrglichkeit von Myrtol standardisiert bei der Langzeitbehandlung der chronischen Bronchitis, Arzneim.-Forsch. Drug Res 1999; 49 (4): 351–8.
72. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systemativ review. BMJ 2001; 322: 1–6.